A RANDOMIZED PHASE II STUDY ON BEVACIZUMAB VERSUS BEVACIZUMAB PLUS LOMUSTINE VERSUS LOMUSTINE SINGLE AGENTIN RECURRENT GLIOBLA STOMA: THE DUTCH BELOB STUDY

被引：0

作者：

Taal, Walter ^{[1
]}

Oosterkamp, H. ^{[2
]}

Walenkamp, Annemieke ^{[3
]}

Beerenpoot, Lucas ^{[4
]}

Hanse, Monique ^{[5
]}

Buter, Jan ^{[6
]}

Honkoop, Aafke ^{[7
]}

Boerman, Dolf ^{[8
]}

de Vos, Filip ^{[9
]}

Jansen, R. ^{[10
]}

van der Berkmortel, Franchette ^{[11
]}

Brandsma, Dieta ^{[12
]}

Enting, Roelien ^{[3
]}

Kros, Johan ^{[1
]}

Bromberg, Jacoline ^{[1
]}

van Heuvel, Irene ^{[1
]}

Smits, Marion ^{[1
]}

van der Holt, Ronnie ^{[1
]}

Vernhout, Rene ^{[1
]}

van den Bent, Martin ^{[1
]}

机构：

[1] ErasmusMC, Rotterdam, Netherlands

[2] MCHaaglanden, The Hague, Netherlands

[3] Univ Med Ctr Groningen, Groningen, Netherlands

[4] St Elizabeth Hosp, Tilburg, Netherlands

[5] Catharina Hosp, Eindhoven, Netherlands

[6] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands

[7] Isala Klin, Zwolle, Netherlands

[8] Rijnstate Hosp, Arnhem, Netherlands

[9] UMCU, Utrecht, Netherlands

[10] MUCM, Maastricht, Netherlands

[11] Atrium Hosp, Heerlen, Netherlands

[12] Dutch Canc Inst, Amsterdam, Netherlands

来源：

NEURO-ONCOLOGY | 2013年 / 15卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：83 / 84

页数：2

共 50 条

[21] SEQUENCE OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST PROGRESSION OF A GLIOBLASTOMA: PHASE II EORTC STUDY 26101
Wick, W.
Stupp, R.
Gorlia, T.
Bendszus, M.
Brandes, A. A.
Voss, M. J.
Le Rhun, E.
Clement, P. M.
Golfinopoulos, V.
van den Bent, M.
[J]. NEURO-ONCOLOGY, 2016, 18 : 11 - 11
[22] ENZASTAURIN VERSUS LOMUSTINE IN THE TREATMENT OF RECURRENT, INTRACRANIAL GLIOBLASTOMA: A PHASE III STUDY
Puduvalli, Vinay K.
Wick, Wolfgang
Chamberlain, Marc
Carpentier, Antoine
Cher, Lawrence
Mason, Warren
Van Den Bent, Martin
Hong, Sam
Thornton, Donald E.
Fine, Howard
[J]. NEURO-ONCOLOGY, 2008, 10 (05) : 825 - 825
[23] A BAYESIAN ADAPTIVE RANDOMIZED PHASE II TRIAL OF BEVACIZUMAB VERSUS BEVACIZUMAB PLUS VORINOSTAT IN ADULTS WITH RECURRENT GLIOBLASTOMA FINAL RESULTS
Puduvalli, Vinay
Wu, Jing
Yuan, Ying
Armstrong, Terri
Wu, Jimin
Giglio, Pierre
Xu, Jihong
Colman, Howard
Walbert, Tobias
Raizer, Jeffrey
Groves, Morris
Iwamoto, Fabio
Tran, David
Avgeropoulos, Nicholas
Paleologos, Nina
Fink, Karen
Peereboom, David
Chamberlain, Marc
Merrell, Ryan
Penas-Prado, Marta
Yung, W. K. Alfred
Gilbert, Mark
[J]. NEURO-ONCOLOGY, 2018, 20 : 13 - 13
[24] Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study
Monk, Bradley J.
Sill, Michael W.
Walker, Joan L.
Darus, Christopher J.
Sutton, Gregory
Tewari, Krishnansu S.
Martin, Lainie P.
Schilder, Jeanne M.
Coleman, Robert L.
Balkissoon, Jai
Aghajanian, Carol
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (19) : 2279 - +
[25] RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Ahluwalia, Manmeet
Peereboom, David
Schilero, Cathy
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
[J]. NEURO-ONCOLOGY, 2018, 20 : 234 - 234
[26] Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
D. H. Heiland
W. Masalha
P. Franco
M. R. Machein
A. Weyerbrock
[J]. Journal of Neuro-Oncology, 2016, 126 : 567 - 575
[27] Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine
Heiland, D. H.
Masalha, W.
Franco, P.
Machein, M. R.
Weyerbrock, A.
[J]. JOURNAL OF NEURO-ONCOLOGY, 2016, 126 (03) : 567 - 575
[28] A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases
Chun, You Jin
Kim, Seong-Geun
Lee, Keun-Wook
Cho, Sang Hee
Kim, Tae Won
Baek, Ji Yeon
Park, Young Suk
Hong, Soojung
Chu, Chong Woo
Beom, Seung-Hoon
Jung, Minkyu
Shin, Sang Joon
Ahn, Joong Bae
[J]. CLINICAL COLORECTAL CANCER, 2020, 19 (03) : E140 - E150
[29] Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Batchelor, Tracy T.
Mulholland, Paul
Neyns, Bart
Nabors, L. Burt
Campone, Mario
Wick, Antje
Mason, Warren
Mikkelsen, Tom
Phuphanich, Surasak
Ashby, Lynn S.
DeGroot, John
Gattamaneni, Rao
Cher, Lawrence
Rosenthal, Mark
Payer, Franz
Juergensmeier, Juliane M.
Jain, Rakesh K.
Sorensen, A. Gregory
Xu, John
Liu, Qi
van den Bent, Martin
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) : 3212 - 3218
[30] A RANDOMIZED PHASE 2 OPEN LABEL STUDY OF NIVOLUMAB PLUS STANDARD DOSE BEVACIZUMAB VERSUS NIVOLUMAB PLUS LOW DOSE BEVACIZUMAB IN RECURRENT GLIOBLASTOMA (GBM)
Ahluwalia, Manmeet
Fallah, Jaleh
Peereboom, David
Schilero, Cathy
Ali, Assad
Forst, Deborah
Wong, Eric
Wen, Patrick
Reardon, David
[J]. NEURO-ONCOLOGY, 2019, 21 : 220 - 220

← 1 2 3 4 5 →